SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Qualified Opinion who wrote (3192)9/19/2002 9:58:54 AM
From: aknahow  Read Replies (1) of 10345
 
Thanks for both links. Had forgotten to listen to the BGEN presentation and did not know about the MS one.

IMO BGEN know how to present. The company is solid and has the resources to market Amevive as well as develop Antegren and other even new drugs in their pipeline. But I learned nothing new about the Amevive delay nor how Antegren is progressing. So far today I would say that whatever was said by anyone at the conference about Antegren did not cause much of a stir as both BGEN and ELN are down slightly.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News